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Abstract
Aims Healthcare services worldwide have been significantly impacted by the COVID-19 pandemic. Recent reports have
shown a decline in hospitalization for emergency cardiac conditions. The impact of the COVID-19 pandemic on hospitalization
and particularly mortality due to acute heart failure has not been thoroughly described.
Methods and results In this single-centre observational study, we examined referrals to the acute heart failure team over a
period of 16 weeks (7 January to 27 April 2020) spanning the ongoing COVID-19 pandemic; 283 patients referred to our acute
heart failure services over the study period were included on the basis of typical symptoms, raised BNP, and echocardiogram.
There was a substantial but statistically non-significant drop in referrals with 164 referred in the 8 weeks before the first UK
death due to COVID-19 on 2March 2020 (BC), compared with 119 referred after (AC) in the subsequent 8 weeks, representing
a 27% reduction overall (P = 0.06). The 30 day case fatality rate was increased from 11% in the BC group compared with 21% in
the AC group (risk ratio = 1.9, 95% confidence interval 1.09–3.3). Age, gender, length of stay, left ventricular ejection fraction,
and N-terminal pro-brain natriuretic peptide were similar between the groups. Admission creatinine, age, and AC cohort status
were found to be univariable predictors of mortality. On multivariate Cox regression analysis, only age (hazard ratio 1.04,
P = 0.03) and AC cohort status (hazard ratio 2.1, P = 0.017) remained significant predictors of mortality. On sensitivity analysis,
this increased mortality was driven by COVID-19 positive status.
Conclusions There was a reduction in referral of patients with acute heart failure with significant increase in mortality in the
8 weeks following the first reported UK death due to COVID-19. The observation of increased mortality does not appear re-
lated to a change in population in terms of demographics, left ventricular ejection fraction, or N-terminal pro-brain natriuretic
peptide. The observed increased mortality appears to be related to the coexistence of COVID19 infection with acute heart fail-
ure. The study highlights the need for widespread preventative and shielding measures particularly in this group of patients
especially in the light of the second wave. Longer follow-up with inclusion of data from other centres and community heart
failure services will be needed.
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Introduction
In response to the COVID-19 pandemic, healthcare services
worldwide have introduced unprecedented measures aimed
to rationalize resources, including postponement of
non-urgent hospital appointment and elective procedures,
and transition to remote consultations to minimize hospital
footfall. Recent reports have shown a decline in hospitaliza-
tion for emergency cardiac conditions such as acute myocar-
dial infarction and heart failure (HF).1–3 Although recent
studies have described the impact of COVID-19 on HF, dem-
onstrating lower hospitalization and higher mortality, there
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are few discrepancies and the data are limited especially from
the UK.4–6 In the UK, HF affects 920 000 people, and carries
significant mortality, with 1 year survival rates estimated at
81%.7–9 The British Society for Heart Failure recommends
that symptomatic inpatients with new or known HF should
be referred to the specialist HF team for assessment and
management.10
Methods
We examined inpatient referrals with suspected acute HF to
the cardiology team in a large NHS hospital in the
south-west of the UK covering a catchment population of ap-
proximately half a million people, over a period of 16 weeks
spanning the ongoing COVID-19 pandemic. Inclusion criteria
were BNP levels >400 pg/mL and/or characteristic signs
and symptoms of HF8,11 alongside echocardiography.
The date of the first coronavirus death in England, 2March
2020, was used as cut-off to define two equally sized groups:
‘before COVID-19’ (BC; 7 January to 2 March 2020, 8 weeks)
and ‘after COVID-19’ (AC; 3March to 27April 2020, 8weeks).12
Data for age, gender, N-terminal pro-brain natriuretic pep-
tide (NT-proBNP), echocardiography results, and length of
stay were collated. Additionally, the Charlson Comorbidity In-
dex was calculated for each patient on review of electronic
notes. Each patient was followed up for 30 days for
all-cause mortality.
Statistical analysis was performed to assess for differences
in baseline demographics, as well as type and severity of HF
between groups. Categorical variables were presented as ab-
solute numbers, percentages, and risk ratio with 95% confi-
dence interval and compared by the χ2 test. Continuous
variables were presented as mean and standard deviation
and compared by Student’s t-test. The association of time
variables to mortality was assessed using Kaplan–Meier
curves and the log-rank test. Univariable and multivariable as-
sociations of risk covariates with mortality were assessed
using Cox proportional hazard regression analyses. An
event-per-variable ratio of 10 was used, and hence, only
variables with P < 0.1 in univariable analyses were used in
multivariable model. Probability values were two sided, and
values of P < 0.05 were considered significant. All analyses
were conducted using SPSS Statistics (SPSS, IBM Corp, USA,
V24) software. The study was registered as a service evalua-
tion audit, and in view of the observational nature of the
study, formal ethical approval was not deemed necessary.
Results
A total of 305 patients were referred to our acute HF services
over the study period. All patients referred were reviewed by
a consultant cardiologist with subspecialization interest in HF.
Based on the consultant review, only those felt to have
features suggestive of acute HF who were subsequently
managed under the care of a cardiologist were included. This
totalled 283 patients (54% male, 81 ± 10 years) in the final
analysis.
Referral pattern and baseline demographics
On review of the referral volume, we observed a substantial,
though statistically non-significant, drop with 164 patients
referred before the first UK death due to COVID-19 (BC),
compared with 119 patients referred after (AC), representing
a 27% reduction overall (P = 0.06).
There was no significant difference in baseline characteris-
tics between the BC and AC groups in terms of age (mean
82 ± 10 vs. 80 ± 11 years, respectively, P = 0.12) or gender
(female 49% vs. 41%, respectively, P = 0.2). Length of stay
did not significantly differ between the BC and AC groups
(14 vs. 13 days, respectively, P = 0.30). There was no differ-
ence in Charlson Comorbidity Index comparing the BC and
AC groups.
Detailed results on demographics and type of HF are
shown in Table 1.
Classification and severity of heart failure
Comparing patients before the first UK COVID-19 death with
after, patients were noted to have similar left ventricular
ejection fraction, 45 ± 10% vs. 43 ± 11%, P = 0.22, with similar
proportions of patients with severe left ventricular systolic
dysfunction [36% (55/164) vs. 41% (49/119), respectively,
P = 0.21]. There was a higher median NT-proBNP level in








Age (years) 82 ± 10 80 ± 11 0.12
Sex (female, %) 49 41 0.2
Previous MI (%) 25 23 0.73
Known HF (%) 69 71 0.68
CCI 8 ± 3 8 ± 3 0.77
Hb (g/dl) 119 ± 23 122 ± 23 0.24
Creatinine
(mg/dL)
120 ± 61 131 ± 72 0.16
Diabetes (%) 27 44 0.002




CCI, Charlson Comorbidity Index; HF, heart failure; LVEF, left ven-
tricular ejection fraction; MI, myocardial infarction.
*P-value < 0.05 denotes significance.
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patients admitted following the first UK COVID-19 death (AC)
compared with before (BC), but this did not reach statistical
significance (4784 vs. 4495 pg/mL, respectively, P = 0.37).
Mortality
Short-term (30 day) case mortality was substantially in-
creased to 21% (25/119) in the AC group compared with
11% (18/164) in the BC group (risk ratio = 1.9, 95% confi-
dence interval 1.09–3.3). Biweekly referrals with mortality
are shown in Figure 1. Figure 2 demonstrates Kaplan–Meier
curve analysis showing significant association between the
time of presentation and mortality (log rank 5.6, P = 0.017).
Univariate and multivariate analysis was performed for the
whole cohort using age, gender, admission haemoglobin, ad-
mission creatinine, COVID-19 status, left ventricular ejection
fraction, BNP, and group (BC or AC) to look at the predictors
of mortality. Only admission creatinine, age, and AC cohort
status were found to be univariable predictors of mortality.
On multivariate Cox regression analysis, only age (hazard ratio
1.04, P = 0.03) and AC cohort status (hazard ratio 2.1,
P = 0.017) remained significant predictors of mortality. On fur-
ther analysis of the effect of age on mortality, in the group
<80 years, the mortality was 6.3% in BC vs. 13.9% in the AC
(log rank 3.7, P = 0.05), and in the group ≥80 years, the mor-
tality was 18% in BC vs. 23.2% in the AC (log rank 2.6, P = 0.11).
COVID-19 status
COVID-19 testing was carried out in 117 patients, of whom 11
(9.4%) had a positive result. Relating this to short-term mor-
tality, 6/11 (54%) of COVID-19-positive patients died within
30 days vs. 27/106 (25%) of COVID-19-negative patients
(P = 0.07).
On sensitivity analysis, excluding the COVID-19-positive pa-
tients, short-term (30 day) case mortality was still higher in
the AC group (18.7%, 21/112) compared with the BC group
(10%, 16/160), but this became statistically non-significant
(P = 0.05).
Discussion
This study examined the short-term mortality in hospitalized
patients with acute HF in relation to the COVID-19 pandemic.
We identify a number of important points.
There was a substantial reduction in referral volume to the
acute HF service during the COVID-19 pandemic with an ap-
proximately 30% decline in inpatient referrals to cardiology
with suspected acute HF after the first UK COVID-19 death.
As reported by Cox et al., the reasons for decreased rates
of hospitalization during the pandemic are multifactorial.5
We suggest that, as reported in other cardiac emergencies,
the drop in admissions for acute HF may reflect public con-
cern regarding social distancing during national lockdown
and anxiety regarding hospital attendance alongside primary
care-led avoidance of hospital referral. Indeed, this is sup-
ported by the drop in referrals being most pronounced at
Figure 2 Kaplan–Meier curve demonstrating significant increase in mor-
tality in cohort of patients following the first reported UK death from
COVID-19.
Figure 1 Biweekly referral pattern, with case fatality rate spanning the
16 weeks before and after the first UK death from COVID-19.
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the time of UK lockdown measures and subsequently increas-
ing slightly following media reports encouraging patients to
seek medical attention if needed, as indicated in Figure 1.
The major finding of this study is a significant increase in
short-term mortality with an almost two-fold in case fatality
rate. On crude comparisons between the groups by demo-
graphics, co-morbidity index, and length of stay, there was
no significant difference between the groups. Although there
was no significant difference in age between the BC and AC
groups, we demonstrate that age appears to be an indepen-
dent predictor of mortality. Furthermore, interestingly, we
detected a more pronounced, almost statistically significant,
increase in mortality in AC vs. BC in the younger (<80 years)
age group compared with the same comparison in the older
group. Previous studies have identified age as a powerful pre-
dictor of mortality in HF.13,14 Our study findings are in line
with another UK study by Cannatà et al. highlighting a reduc-
tion in HF hospitalization in two hospitals in London and sig-
nificantly increased rates of in-hospital mortality during the
COVID-19 pandemic.15 This finding is particularly interesting
as London was a high endemic zone compared with Bristol,
which had a low case volume during the first wave of
COVID-19. In contrast to the UK, a German study by Bollmann
et al. showed relatively lower mortality rates of 7%, com-
pared with our study findings.6 Another Danish study noted
reduced admissions with HF during the pandemic, although
it failed to demonstrate a mortality impact.16 Studies in other
countries have therefore not reported significantly increased
mortality as a result of HF in the COVID-19 pandemic. Finally,
we noted a study by Rey et al., which looked at 3080 patients
with confirmed COVID-19, reporting significant incidence of
acute HF amongst COVID-19 patients, with high reported as-
sociated mortality of 20.5%.17
In terms of HF parameters, left ventricular ejection frac-
tion, proportion of those with severe left ventricular dysfunc-
tion and NT-proBNP were similar between the groups
suggesting a similar clinical picture on admission. It is possible
that the numbers examined are insufficient to demonstrate a
more severe clinical picture and that patients with milder
symptoms were not seeking medical attention or referral to
hospital was being deferred by primary care.
Arguably, the most important aspect demonstrated by this
study is that although patients appear to be well balanced in
most aspects, the exclusion of positive COVID-19 patients
from the analysis rendered the mortality difference non-sig-
nificant. This suggests that the coexistence of acute HF and
confirmed COVID-19 appears to confer a significant poorer
prognosis.
This is a novel finding that would ideally be subject to fur-
ther validation in larger groups but underlines the need for
preventative measures to avoid infection particularly to pa-
tients with chronic HF. Longer follow-up and, given the re-
ported striking regional disparity in cases, inclusion of data
from other centres as well as data from the community HF
service would be needed to fully evaluate this interaction
and understand the true implications of the pandemic on
emergency cardiac presentations.
Limitations
• This was a registry and therefore suffers the inherent
biases of real-world observational study with variations in
available data and management. However, we feel that
this represents important novel data upon which to build.
• We compared patients before and after the first UK death
due to COVID-19. We recognize that there may be sea-
sonal variability in acute HF admissions. However, as the
acute HF referral pathway at our institution was imple-
mented in May 2019, it was not possible to make a com-
parison with previous years.
• We recognize that not all patients in the AC group were
tested for COVID-19. As the pandemic developed, patients
were routinely tested on admission to hospital; however,
earlier, patients tested were those with symptoms of
COVID-19 or positive contacts. We acknowledge that there
are a proportion of untested patients who may have been
COVID-19 positive. Moreover, the symptoms of COVID-19
and acute HF overlap, and hence, clear distinction be-
tween the two may have been missed. The study by Rey
et al. demonstrated a high prevalence of acute HF in
COVID-19-positive patients with significantly increased
mortality.17
• The recorded cause of death was not reported in this
study. We recognize that this would have provided addi-
tional insight, particularly in those undergoing
post-mortem examinations.
• The study was performed at a district general hospital, and
some patients were nursed on mixed cardiology/general
medicine wards under the care of a consultant cardiolo-
gist. As a result, sensitivity analysis comparing outcome
of patients according to type of ward was not possible.
Conclusions
This study demonstrates a reduction in referrals for acute HF
since the onset of the UK COVID-19 crisis with a significant in-
crease in short-term mortality after the first UK death. Impor-
tantly, our data demonstrate the prognostic impact of
positive COVID-19 status on mortality in patients presenting
with acute HF.
Perspective
• This study highlights the need for widespread preventative
and shielding measures particularly in this group of
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patients presenting with acute HF especially in the light of
second wave.
• Longer follow-up with inclusion of data from other centres
and community HF services will be needed to fully evalu-
ate this effect.
• Moving forward, we propose that future work could inves-
tigate whether countermeasures adopted in response to
the pandemic, such as routine screening of inpatients for
COVID-19, media adverts highlighting the importance of
seeking medical attention, or telemedicine (virtual clinics),
have impacted on referral patterns and longer-term
mortality.
Acknowledgements
We would like to thank the entire cardiology team at North
Bristol NHS Trust including the heart failure nursing team





All authors take responsibility for all aspects of the reliability
and freedom from bias of the data presented and their
discussed interpretation.
References
1. Solomon M, McNulty E, Rana J, Leong T,
Lee C, Sung S-H, Ambrosy A, Sidney S,
Go A. The COVID-19 pandemic and the
incidence of acute myocardial infarction.
NEJM 2020; 383: 691–693.
2. Garcia S, Albaghdadi M, Meraj P,
Schmidt C, Garberich R, Jaffer F, Dixon
S, Rade J, Tannenbaum M, Jenny C,
Huang P, Henry T. Reduction in
ST-segment elevation cardiac catheteri-
zation laboratory activations in the
United States during COVID-19 pan-
demic. JACC 2020; 75: 0–1.
3. Hall ME, Vaduganathan M, Khan MS,
Papadimitriou L, Long RC, Hernandez
GA, Moore CK, Lennep BW, Mcmullan
MR, Butler J. Reductions in heart failure
hospitalizations during the COVID-19
pandemic. J Card Fail [Internet] 2020;
26: 462–463.
4. Bromage DI, Cannatà A, Rind IA,
Gregorio C, Piper S, Shah AM,
McDonagh TA. The impact of COVID-19
on heart failure hospitalization and
management: report from a Heart Fail-
ure Unit in London during the peak of
the pandemic. Eur J Heart Fail 2020;
22: 978–984.
5. Cox ZL, Lai P, Lindenfeld J. Decreases in
acute heart failure hospitalizations dur-
ing COVID-19. Eur J Heart Fail 2020:
6–7.
6. Bollmann A, Hohenstein S, Meier-
Hellmann A, Kuhlen R, Hindricks G.
Emergency hospital admissions and in-
terventional treatments for heart failure
and cardiac arrhythmias in Germany
during the Covid-19 outbreak: insights
from the German-wide Helios hospital
network. Eur Hear J Qual care Clin out-
comes 2020; 6: 221–222.
7. British Heart Foundation. BHF statistics
factsheet—UK. 2020; Available from:
https://www.bhf.org.uk/what-we-do/
our-research/heart-statistic
8. National Institute for Health and Care
Excellence (NICE). Acute heart failure:
diagnosis and management. 2014.
9. Taylor CJ, Ordóñez-Mena JM, Roalfe
AK, Lay-Flurrie S, Jones NR, Marshall
T, Hobbs FR. Trends in survival after a
diagnosis of heart failure in the United
Kingdom 2000–2017: population based
cohort study. BMJ 2019; 364: 1–10.
10. British Society for Heart Failure. Reten-
tion of essential heart failure services
during COVID-19 pandemic: a position
statement from the British Society for
Heart Failure. 2020
11. Cox Z, Lewis C, Lai P, Lenihan D. Valida-
tion of an automated electronic algo-
rithm and “dashboard” to identify and
characterize decompensated heart fail-
ure admissions across a medical center.
Am Heart J 2017; 183: 40–48.
12. Coronavirus (COVID-19) in the UK. UK
coronavirus (COVID-19) cases in
the UK. UK Crown. Available at:
https://coronavirus.data.gov.uk/
13. Pocock SJ, Wang D, Pfeffer MA, Yusuf S,
McMurray JJV, Swedberg KB, Ostergren
J, Michelson EL, Pieper KS, Granger CB.
Predictors of mortality and morbidity in
patients with chronic heart failure. Eur
Heart J 2006; 27: 65–75.
14. Lee DS, Austin PC, Rouleau JL, Liu PP,
Naimark D. Predicting mortality among
patients hospitalized for heart
failure derivation and validation of a
clinical model. JAMA 2003; 290:
2581–2587.
15. Cannatà A, Bromage DI, Rind IA,
Gregorio C, Bannister C, Albarjas M,
Piper S, Shah AM, McDonagh TA. Tem-
poral trends in decompensated heart
failure and outcomes during COVID-19:
a multisite report from heart failure re-
ferral centres in London. Eur J Heart Fail
2020: 1–6.
16. Andersson C, Andersson C, Gerds T,
Fosbøl E, Phelps M, Andersen J,
Lamberts M, Holt A, Butt JH, Madelaire
C, Gislason G, Torp-Pedersen C.
Incidence of new-onset and worsening
heart failure before and after the
COVID-19 epidemic lockdown in
Denmark: a nationwide cohort study.
Circ Heart Fail 2020;(June; 13:
e007274.
17. Rey JR, Caro-codón J, Rosillo SO,
Iniesta ÁM, Castrejón-castrejón S,
Marco-clement I, Martín-Polo L,
Merino-Argos C, Rodríguez-Sotelo L,
García-Veas JM, Martínez-Marín LA.
Heart failure in COVID-19 patients:
prevalence, incidence and prognostic
implications. Eur J Heart Fail 2020:
1–11.
Impact of COVID-19 in acute heart failure 1695
ESC Heart Failure 2021; 8: 1691–1695
DOI: 10.1002/ehf2.13158
